{"nctId":"NCT02008565","briefTitle":"Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)","startDateStruct":{"date":"2014-02"},"conditions":["Fecal Incontinence"],"count":300,"armGroups":[{"label":"Placebo - Exercise plus Biofeedback","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Behavioral: Anal exercises with biofeedback"]},{"label":"Loperamide - Exercise plus Biofeedback","type":"EXPERIMENTAL","interventionNames":["Drug: Loperamide","Behavioral: Anal exercises with biofeedback"]},{"label":"Placebo - Education Only","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Behavioral: Usual Care"]},{"label":"Loperamide - Education Only","type":"EXPERIMENTAL","interventionNames":["Drug: Loperamide","Behavioral: Usual Care"]}],"interventions":[{"name":"Loperamide","otherNames":["Imodium"]},{"name":"Placebo","otherNames":["Inactive Drug"]},{"name":"Anal exercises with biofeedback","otherNames":[]},{"name":"Usual Care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years\n* Fecal incontinence defined as any uncontrolled loss of liquid or solid fecal material that occurs at least monthly over the last 3 months that is bothersome enough to desire treatment\n\nExclusion Criteria:\n\n* Stool consistency over the last 3 months that includes items 1 or 7 based on the Bristol Stool form scale\n* Current or past diagnosis of colorectal or anal malignancy\n* Diagnosis of inflammatory bowel disease\n* Current or history of rectovaginal fistula or cloacal defect\n* Rectal prolapse (mucosal or full thickness)\n* Prior removal or diversion of any portion of colon or rectum\n* Prior pelvic floor or abdominal radiation\n* Refusal or inability to provide written consent\n* Inability to conduct telephone interviews conducted in English or Spanish\n* Fecal impaction by exam\n* Untreated pelvic organ prolapse beyond the hymen; Patients with prolapse beyond the hymen who are currently using a pessary are eligible\n* Incontinence only to flatus\n* Has taken any loperamide (Imodium®) or diphenoxylate plus atropine (Lomotil®) in the last 30 days\n* Previously received and failed treatment of fecal incontinence using loperamide (Imodium®) or diphenoxylate plus atropine (Lomotil®) over the last 3 months\n* Current supervised anal sphincter exercise/pelvic floor muscle training with biofeedback\n* Previously received and failed treatment of fecal incontinence using supervised anal sphincter exercise/pelvic floor muscle training with biofeedback\n* Previous allergy or intolerance to loperamide\n* Pregnant, nursing, or planning to become pregnant before the end of the study follow-up period.\n* Childbirth within the last 3 months\n* Currently taking anti-retroviral drugs\n* Neurological disorders known to affect continence, including spinal cord injury, advanced multiple sclerosis or Parkinson's disease and debilitating stroke\n* Known diagnosis of hepatic impairment\n* Chronic abdominal pain in the absence of diarrhea","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline St. Mark's (Vaizey) Score","description":"The primary outcome measure for all study arms is the change from baseline in St. Mark's (Vaizey) Score 24 weeks after treatment initiation to compare the marginal outcomes of anal exercise with biofeedback to usual care and loperamide to placebo.\n\nThe St. Mark's (Vaizey) score, published in 1999, is commonly used in clinical studies and reports and was based on the Jorge-Wexner score but added two further items for assessment: the use of constipating medication and the presence of fecal urgency. Minimum score is 0 = perfect continence; maximum score is 24 = totally incontinent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":null},{"groupId":"OG001","value":"-4.4","spread":null},{"groupId":"OG002","value":"-4.5","spread":null},{"groupId":"OG003","value":"-3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":null},{"groupId":"OG001","value":"-5.9","spread":null},{"groupId":"OG002","value":"-6.2","spread":null},{"groupId":"OG003","value":"-4.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life on Colorectal-Anal Distress Inventory (CRADI)","description":"The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1) Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2) Colorectal Anal Distress Inventory (range: 0-100), and 3) Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Change = (Week \\[12, 24\\] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":null},{"groupId":"OG001","value":"-13.1","spread":null},{"groupId":"OG002","value":"-16.9","spread":null},{"groupId":"OG003","value":"-4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.5","spread":null},{"groupId":"OG001","value":"-15.7","spread":null},{"groupId":"OG002","value":"-21.7","spread":null},{"groupId":"OG003","value":"-15.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Colorectal-Anal Subscale of the Pelvic Floor Impact Questionnaire Short Form (CRAIQ) Score","description":"The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Change = (Week \\[12, 24\\] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":null},{"groupId":"OG001","value":"-10.8","spread":null},{"groupId":"OG002","value":"-15.8","spread":null},{"groupId":"OG003","value":"-12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.3","spread":null},{"groupId":"OG001","value":"-32.4","spread":null},{"groupId":"OG002","value":"-41.6","spread":null},{"groupId":"OG003","value":"-17.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Accident-free Days at 12 and 24 Weeks","description":"Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of accident-free days at 12 and 24 weeks and the number of accident-free days at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"1.7","spread":null},{"groupId":"OG003","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"1.7","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Pad-change Leaks Per Day at 12 and 24 Weeks","description":"Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per day resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-0.2","spread":null},{"groupId":"OG002","value":"-0.3","spread":null},{"groupId":"OG003","value":"-0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.1","spread":null},{"groupId":"OG002","value":"-0.4","spread":null},{"groupId":"OG003","value":"-0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Pad-change Leaks Per Week at 12 and 24 Weeks","description":"Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per week resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":null},{"groupId":"OG001","value":"-1.1","spread":null},{"groupId":"OG002","value":"-1.3","spread":null},{"groupId":"OG003","value":"-1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":null},{"groupId":"OG001","value":"-0.7","spread":null},{"groupId":"OG002","value":"-2.2","spread":null},{"groupId":"OG003","value":"-2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Total Number of Leaks Per Day at 12 and 24 Weeks","description":"Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in daily average FI episodes at 12 and 24 weeks and the daily average FI episodes at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at 3 complete days, not necessarily consecutive, for follow-up diaries).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-0.7","spread":null},{"groupId":"OG002","value":"-0.9","spread":null},{"groupId":"OG003","value":"-1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":null},{"groupId":"OG001","value":"-0.7","spread":null},{"groupId":"OG002","value":"-1.0","spread":null},{"groupId":"OG003","value":"-1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fecal Incontinence Severity Index (FISI) Score","description":"The Modified Manchester Health Questionnaire (MMHQ) includes the 4-item Fecal Incontinence Severity Index (FISI), which measures the severity of liquid, solid, mucus, or gas incontinence that occurs from \"2 or more times per day,\" \"once per day,\" \"2 or more times per week,\" \"once a week,\" to \"1-3 times per month.\" Patient-weighted scores were used to determine severity and scores ranged from 0-61, with higher scores indicating worse fecal incontinence (FI) severity. An FISI score of 0 indicated continence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":null},{"groupId":"OG001","value":"-10.6","spread":null},{"groupId":"OG002","value":"-14.4","spread":null},{"groupId":"OG003","value":"-7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.1","spread":null},{"groupId":"OG001","value":"-15.0","spread":null},{"groupId":"OG002","value":"-19.2","spread":null},{"groupId":"OG003","value":"-20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Improvement in Patient Global Impression of Improvement (PGI-I) Score","description":"The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better), or 3 (a little better).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"61","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Resting Anal Canal Pressures (mm of Hg) at 2 cm, 1 cm, and 0 cm Insertion at 12 and 24 Weeks","description":"Based on data collected from the manometry form, the outcome variable is computed as the difference in resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at 12 and 24 weeks and resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null},{"groupId":"OG001","value":"49.4","spread":null},{"groupId":"OG002","value":"51.1","spread":null},{"groupId":"OG003","value":"46.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"47.8","spread":null},{"groupId":"OG002","value":"45.7","spread":null},{"groupId":"OG003","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"76.3","spread":null},{"groupId":"OG002","value":"73.6","spread":null},{"groupId":"OG003","value":"73.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"74.6","spread":null},{"groupId":"OG002","value":"67.1","spread":null},{"groupId":"OG003","value":"72.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Volume of Air (mL) at First Sensation for Perception of Rectal Distention at 12 and 24 Weeks","description":"Based on data collected from the manometry form, the outcome variable is computed as the difference in volume of air (mL) at first sensation for perception of rectal distention at 12 and 24 weeks and volume of air (mL) at first sensation for perception of rectal distention at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"22.7","spread":null},{"groupId":"OG002","value":"21.6","spread":null},{"groupId":"OG003","value":"25.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":null},{"groupId":"OG001","value":"24.5","spread":null},{"groupId":"OG002","value":"21.6","spread":null},{"groupId":"OG003","value":"23.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Volume of Air (mL) at Urge to Defecate at 12 and 24 Weeks","description":"Based on data collected from the manometry form, the outcome variable is computed as the difference in maximum tolerable rectal volume of air (mL) at 12 and 24 weeks and maximum tolerable rectal volume of air (mL) at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3","spread":null},{"groupId":"OG001","value":"66.9","spread":null},{"groupId":"OG002","value":"73.0","spread":null},{"groupId":"OG003","value":"71.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null},{"groupId":"OG001","value":"78.4","spread":null},{"groupId":"OG002","value":"77.3","spread":null},{"groupId":"OG003","value":"73.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Maximum Anal Pressures During Squeeze With the Catheter at the HPZ at 12 and 24 Weeks","description":"Based on data collected from the manometry form, the outcome variable will be computed as the difference in maximum anal pressures during squeeze with the catheter at the high pressure zone (HPZ) at 12 and 24 weeks and maximum anal pressures during squeeze with the catheter at the HPZ at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"76.3","spread":null},{"groupId":"OG002","value":"73.6","spread":null},{"groupId":"OG003","value":"73.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"74.6","spread":null},{"groupId":"OG002","value":"67.1","spread":null},{"groupId":"OG003","value":"72.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":86},"commonTop":["Constipation","Urinary tract infection","Diarrhoea","Abdominal pain","Abdominal distension"]}}}